Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 5.6% in October

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 196,500 shares, a growth of 5.6% from the October 15th total of 186,100 shares. Based on an average trading volume of 77,200 shares, the short-interest ratio is presently 2.5 days. Approximately 1.4% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th.

Insider Buying and Selling at Coya Therapeutics

In related news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the transaction, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have purchased 9,510 shares of company stock worth $69,615. Company insiders own 9.80% of the company’s stock.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in COYA. Vanguard Group Inc. grew its stake in Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Gilbert & Cook Inc. acquired a new position in shares of Coya Therapeutics during the 2nd quarter worth approximately $61,000. Renaissance Technologies LLC purchased a new stake in Coya Therapeutics in the 2nd quarter valued at approximately $101,000. GHP Investment Advisors Inc. acquired a new stake in Coya Therapeutics during the 3rd quarter valued at $169,000. Finally, Geode Capital Management LLC increased its position in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares in the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Price Performance

Shares of NASDAQ:COYA traded up $0.01 during trading on Tuesday, reaching $6.08. 57,312 shares of the company’s stock traded hands, compared to its average volume of 71,725. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.69. The company has a 50-day simple moving average of $7.12 and a 200-day simple moving average of $6.95.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. As a group, equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.